National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 49 of 66
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
NCT00062101
Oblimersen in Treating Patients With Merkel Cell Carcinoma
NCT00079131
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00075881
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
NCT00077181
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
NCT00077467
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00075751
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00077194
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
NCT00079014
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
NCT00075400
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
NCT00085410
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
NCT00079443
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
NCT00079326
Collection of Tissue Samples for Study of Multidrug Resistance
NCT00880503
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
NCT00085111
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
NCT00077298
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00075647
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00075439
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
NCT00074243
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00077155
Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00088959
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00072566
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00085124
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma
NCT00075634
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
NCT00075491
Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies
NCT00341263
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis
NCT00646555
Recontacting Participants in the Observing Protein and Energy Nutrition (OPEN) Study: Re-OPEN
NCT00339677
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT00070447
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
NCT00070525
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
NCT00075504
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
NCT00074321
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT00058461
A Phase II Study of UCN-01 in Metastatic Melanoma
NCT00072189
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
NCT00068692
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00055757
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
NCT00072163
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
NCT00074308
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
NCT00071058
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
NCT00072150
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
NCT00068783
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00068588
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
NCT00060437
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00053183
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
NCT00072137
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
NCT00071942
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
NCT00069238
Cervical Cancer Early Endpoints and Determinants
NCT00339989
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT00070551
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
NCT00066742
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
NCT00072085
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.